O
Optellum
AI software for early lung cancer diagnosis
About Optellum
Optellum is an Oxford-based medtech company that develops AI clinical decision support software for the early diagnosis of lung cancer. Its software helps hospital care teams find patients with lung nodules, assess their cancer risk and track their follow-up, so more cancers are treated at an early stage.
Its main product, Virtual Nodule Clinic (VNC), scans radiology reports with natural language processing to find nodule patients, pulls CT images and reports from hospital EHR and PACS systems, and manages triage and follow-up. It includes Lung Cancer Prediction (LCP) AI, which applies deep learning and radiomics to CT scans to give a malignancy risk score. VNC is FDA-cleared, CE and UKCA marked and TGA-approved.
Customers are hospitals and health systems in the US, the UK and Europe, mainly pulmonology, radiology and thoracic surgery teams. Optellum sells its software to these providers, and US use of the LCP score is reimbursable under CMS codes. It also works with medtech and pharma partners on research and oncology patient identification.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2016
- Headquarters
- Oxford, United Kingdom
- Employees
- 51
- Open positions
- 1
- Dealroom signal
- 76.4/100
- Industry
- Health
- Sub-industry
- BioTechnology, Medical Devices, Health Platform
- Sector
- Biotech & Life Sciences, Risk Management, Biotechnology, Oncology
- Technology
- Artificial Intelligence, Deep Tech, Machine Learning, Deep Learning, Nanotech
- Business model
- SaaS
- Client focus
- B2B
News
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VC✓Equity / VC | Nov 2025 | $5.7M | $23M | Undisclosed | ↗ |
| LATE VC✓Equity / VC | Jul 2025 | $1.8M | $37M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Optellum is 8.6K monthly website visits, down 3.4% over the last three months. Optellum's team grew 0% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
European Innovation Council
EIT Health
Series A7 investors entered at this stage
Luminous Ventures
Mercia Asset Management
Intuitive Ventures
The Oxford Trust
IQ Capital
Black Opal Ventures
St John’s College
Other known investors7 additional known investors
University of Oxford
Tech Nation- BLBXR Partners LLP
Charles Wiles
Mercia Ventures- MBMichael Brady
Oliver Keown
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Optellum on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Optellum’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.